XM اپنی سروسز امریکہ کے شہریوں کو فراہم نہیں کرتا ہے۔
S
S

Sage


خبر

U.S. STOCKS Avery Dennison, Snap-On, Avadel Pharma

BUZZ-U.S. STOCKS ON THE MOVE-Avery Dennison, Snap-On, Avadel Pharma Wall Street rose on Thursday, with the S&P 500 and the Dow briefly reaching record highs, as chip stocks surged on TSMC's upbeat forecast and stronger-than-expected monthly retail sales indicated a robust U.S. consumer. .N At 13:36 ET, the Dow Jones Industrial Average .DJI was up 0
A
B
C
E
I
N
N
S
S
S
U
U
U
U
A
E

U.S. STOCKS Avery Dennison, Snap-On, Avadel Pharma

BUZZ-U.S. STOCKS ON THE MOVE-Avery Dennison, Snap-On, Avadel Pharma Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street gained on Thursday, with the S&P 500 and the Dow touching intraday record highs, driven by TSMC's upbeat forecast and a bigger-than-expected rise in monthly retail sales indicating a strong U.S.
A
B
C
E
I
N
N
R
S
S
S
U
U
U
U
T
U
W
W
A
E
M
S

Sage to lay off more than half of R&D team, shares fall

BUZZ-Sage to lay off more than half of R&D team, shares fall ** Sage Therapeutics' shares SAGE.O fall 5.5% to $6.87 in morning trade ** Co says it will lay off more than 165 employees, including more than half of its R&D team, as part of reorganization plan ** To prioritize launch of postpartum depression pill Zurzuvae, which has been jointly devel
B
S

SAGE Therapeutics Approved Separation Of CFO Kimi Iguchi And Anne Cook, Senior VP, General Counsel, And Secretary

BRIEF-SAGE Therapeutics Approved Separation Of CFO Kimi Iguchi And Anne Cook, Senior VP, General Counsel, And Secretary Oct 17 (Reuters) - SAGE Therapeutics Inc SAGE.O : SAGE THERAPEUTICS: APPROVED SEPARATION OF KIMI IGUCHI, CFO, AND ANNE MARIE COOK, SENIOR VP, GENERAL COUNSEL, AND SECRETARY Source text for Eikon: [ID:n0001193125-24-238425] Further
S

SAGE Therapeutics Says To Reduce Workforce By About 33%

BRIEF-SAGE Therapeutics Says To Reduce Workforce By About 33% Oct 17 (Reuters) - SAGE Therapeutics Inc SAGE.O : SAGE THERAPEUTICS ANNOUNCES STRATEGIC REORGANIZATION TO PRIORITIZE ZURZUVAE® COMMERCIALIZATION AND FOCUS ITS DEVELOPMENT PORTFOLIO SAGE THERAPEUTICS INC - TO REDUCE WORKFORCE BY APPROXIMATELY 33% SAGE THERAPEUTICS INC - REORGANIZATION TO
S

Sage Therapeutics' CFO to leave, drugmaker to lay off over 165 employees

UPDATE 2-Sage Therapeutics' CFO to leave, drugmaker to lay off over 165 employees Adds details on CFO leaving company in paragraphs 1, 3 and background in paragraphs 8-10 Oct 17 (Reuters) - Sage Therapeutics SAGE.O said on Thursday its finance chief will leave the company and the drugmaker plans to lay off more than 165 employees as part of a reorganization plan that aims to focus on the launch of its postpartum depression pill.
B
S

Sage Therapeutics to lay off more than 165 employees

Sage Therapeutics to lay off more than 165 employees Oct 17 (Reuters) - Sage Therapeutics SAGE.O said on Thursday it will lay off more than 165 employees or about 33% of the company's total workforce. Reporting by Sriparna Roy in Bengaluru; Editing by Shounak Dasgupta
S

U.S. Autozone, State Street, UnitedHealth

U.S. RESEARCH ROUNDUP-Autozone, State Street, UnitedHealth Oct 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Autozone, State Street and UnitedHealth, on Wednesday. HIGHLIGHTS * Autozone Inc AZO.N : Roth MKM resumes coverage with buy rating; price target $3,634 * Goldman Sachs GS.N : Barclays raises target price to $588 from $565 * ServiceNow Inc NOW.N : Jefferies raises target price to $1,100 from $900 * State St
C
G
S
T
F
G
S
A

U.S. Aflac, Lincoln National, Prudential Financial

U.S. RESEARCH ROUNDUP-Aflac, Lincoln National, Prudential Financial Oct 9 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Aflac, Lincoln National and Prudential Financial, on Wednesday. HIGHLIGHTS * Aflac Inc AFL.N : TD Cowen initiates coverage with hold rating; price target $102 * Corebridge Financial Inc CRBG.N : TD Cowen initiates coverage with buy rating * Lincoln National Corp LNC.N : TD Cowen initiates coverage
A
B
G
H
N
P
S
S
S
A
V
A
A
E
G
L
M

U.S. STOCKS Nvidia, Roblox, Honeywell

BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Roblox, Honeywell Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes opened higher on Tuesday, as investors shifted their attention to the upcoming third-quarter earnings season and inflation data for hints on the Federal Reserve's future rate decisions.
C
M
M
N
Q
S
L
R
W
U
U
E
S
T

U.S. STOCKS Copper miners, PepsiCo, Casinos

BUZZ-U.S. STOCKS ON THE MOVE-Copper miners, PepsiCo, Casinos Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 U.S. stock index futures bounced back on Tuesday from a selloff in the previous session, as investors turned their focus on key inflation data and third-quarter earnings later this week for fresh insights into the Federal Reserve's interest rate path.
M
M
P
Q
S
L
R
W
U
E
T

Sage Therapeutics scraps Alzheimer’s drug development after trial fails; shares slide

UPDATE 3-Sage Therapeutics scraps Alzheimer’s drug development after trial fails; shares slide Adds background in paragraph 2, analyst comment in paragraph 5; updates shares Oct 8 (Reuters) - Sage Therapeutics SAGE.O said on Tuesday it would stop developing its experimental drug, dalzanemdor, for Alzheimer's disease after it failed to meet the main goal of a late-stage trial, sending its shares down 10% in premarket trading.
B
S

Sage falls on plans to stop development of Alzheimer's disease drug

BUZZ-Sage falls on plans to stop development of Alzheimer's disease drug ** Shares of Sage Therapeutics SAGE.O down 13% at $5.86 before the bell ** SAGE plans to stop further development of its experimental drug, dalzanemdor, for Alzheimer's disease after it failed to meet the main goal of a mid-stage study ** Dalzanemdor was being tested to treat
S

Sage Announces Results From Phase 2 Study Of Dalzanemdor In Treatment Of Mild Cognitive Impairment And Mild Dementia In Alzheimer’s Disease

BRIEF-Sage Announces Results From Phase 2 Study Of Dalzanemdor In Treatment Of Mild Cognitive Impairment And Mild Dementia In Alzheimer’s Disease Oct 8 (Reuters) - SAGE Therapeutics Inc SAGE.O : SAGE THERAPEUTICS ANNOUNCES TOPLINE RESULTS FROM THE PHASE 2 LIGHTWAVE STUDY OF DALZANEMDOR (SAGE-718) IN THE TREATMENT OF MILD COGNITIVE IMPAIRMENT AND
S

Sage Therapeutics to discontinue development of Alzheimer’s drug

Sage Therapeutics to discontinue development of Alzheimer’s drug Oct 8 (Reuters) - Sage Therapeutics SAGE.O said on Tuesday it will discontinue the development of its Alzheimer's disease drug as it did not meet the main goal in a mid-stage trial. Reporting by Christy Santhosh; Editing by Pooja Desai
S

Sage Therapeutics falls after Biogen terminates tremor drug partnership

BUZZ-Sage Therapeutics falls after Biogen terminates tremor drug partnership ** Shares of drug developer Sage Therapeutics SAGE.O fall 1% to $6.95 premarket ** Company says partner Biogen BIIB.O has terminated a licensing deal for Sage's experimental drug to treat essential tremor, effective February 2025 ** Sage had discontinued development of the
B
S

SAGE Therapeutics Announces Discontinuation Of The Collaboration With Biogen On The Sage-324 Program

BRIEF-SAGE Therapeutics Announces Discontinuation Of The Collaboration With Biogen On The Sage-324 Program Sept 26 (Reuters) - SAGE Therapeutics Inc SAGE.O : SAGE THERAPEUTICS ANNOUNCES DISCONTINUATION OF THE COLLABORATION WITH BIOGEN ON THE SAGE-324 PROGRAM SAGE THERAPEUTICS INC - BIOGEN TERMINATES RIGHTS UNDER SAGE-324 PROGRAM SAGE THERAPEUTICS I
S

Incorrect research alert on Sage Therapeutics Inc withdrawn

ADVISORY-Incorrect research alert on Sage Therapeutics Inc withdrawn An alert on J.P. Morgan cutting its price target on Sage Therapeutics Inc SAGE.O is incorrect and has been withdrawn. The brokerage lowered its PT on Sage Group PLC, an unrelated company. For the correct research alert on Sage Group PLC, click here . STORY_NUMBER: FWN3L714D STORY_
S

U.S. CH Robinson Worldwide, Dayforce, Entegris

U.S. RESEARCH ROUNDUP-CH Robinson Worldwide, Dayforce, Entegris Aug 1 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CH Robinson Worldwide, Dayforce and Entegris, on Thursday. HIGHLIGHTS * CH Robinson Worldwide Inc CHRW.O : JP Morgan raises to overweight from neutral * Dayforce Inc DAY.N : Piper Sandler raises to overweight from neutral * Entegris Inc ENTG.O : Seaport Research Partners raises to buy from neutral * M
B
C
D
E
M
Q
S
V
A
C
D
E
L
T
P
W
A
B
C

SAGE Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

SAGE Therapeutics Inc reports results for the quarter ended in June - Earnings Summary SAGE Therapeutics Inc SAGE.OQ reported a quarterly adjusted loss of $1.70​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $-2.68. The mean expectation of twenty analysts for the quarter was for a loss of $1.66 per share.
S



شرائط

مشہور اثاثے

دستبرداری: XM Group کے ادارے ہماری آن لائن تجارت کی سہولت تک صرف عملدرآمد کی خدمت اور رسائی مہیا کرتے ہیں، کسی شخص کو ویب سائٹ پر یا اس کے ذریعے دستیاب کانٹینٹ کو دیکھنے اور/یا استعمال کرنے کی اجازت دیتا ہے، اس پر تبدیل یا توسیع کا ارادہ نہیں ہے ، اور نہ ہی یہ تبدیل ہوتا ہے یا اس پر وسعت کریں۔ اس طرح کی رسائی اور استعمال ہمیشہ مشروط ہوتا ہے: (i) شرائط و ضوابط؛ (ii) خطرہ انتباہات؛ اور (iii) مکمل دستبرداری۔ لہذا اس طرح کے مواد کو عام معلومات سے زیادہ کے طور پر فراہم کیا جاتا ہے۔ خاص طور پر، براہ کرم آگاہ رہیں کہ ہماری آن لائن تجارت کی سہولت کے مندرجات نہ تو کوئی درخواست ہے، اور نہ ہی فنانشل مارکیٹ میں کوئی لین دین داخل کرنے کی پیش کش ہے۔ کسی بھی فنانشل مارکیٹ میں تجارت میں آپ کے سرمائے کے لئے ایک خاص سطح کا خطرہ ہوتا ہے۔

ہماری آن لائن تجارتی سہولت پر شائع ہونے والے تمام مٹیریل کا مقصد صرف تعلیمی/معلوماتی مقاصد کے لئے ہے، اور اس میں شامل نہیں ہے — اور نہ ہی اسے فنانشل، سرمایہ کاری ٹیکس یا تجارتی مشورے اور سفارشات؛ یا ہماری تجارتی قیمتوں کا ریکارڈ؛ یا کسی بھی فنانشل انسٹرومنٹ میں لین دین کی پیشکش؛ یا اسکے لئے مانگ؛ یا غیر متنازعہ مالی تشہیرات پر مشتمل سمجھا جانا چاہئے۔

کوئی تھرڈ پارٹی کانٹینٹ، نیز XM کے ذریعہ تیار کردہ کانٹینٹ، جیسے: راۓ، خبریں، تحقیق، تجزیہ، قیمتیں اور دیگر معلومات یا اس ویب سائٹ پر مشتمل تھرڈ پارٹی کے سائٹس کے لنکس کو "جیسے ہے" کی بنیاد پر فراہم کیا جاتا ہے، عام مارکیٹ کی تفسیر کے طور پر، اور سرمایہ کاری کے مشورے کو تشکیل نہ دیں۔ اس حد تک کہ کسی بھی کانٹینٹ کو سرمایہ کاری کی تحقیقات کے طور پر سمجھا جاتا ہے، آپ کو نوٹ کرنا اور قبول کرنا ہوگا کہ یہ کانٹینٹ سرمایہ کاری کی تحقیق کی آزادی کو فروغ دینے کے لئے ڈیزائن کردہ قانونی تقاضوں کے مطابق نہیں ہے اور تیار نہیں کیا گیا ہے، اسی طرح، اس پر غور کیا جائے گا بطور متعلقہ قوانین اور ضوابط کے تحت مارکیٹنگ مواصلات۔ براہ کرم یقینی بنائیں کہ آپ غیر آزاد سرمایہ کاری سے متعلق ہماری اطلاع کو پڑھ اور سمجھ چکے ہیں۔ مذکورہ بالا معلومات کے بارے میں تحقیق اور رسک وارننگ ، جس تک رسائی یہاں حاصل کی جا سکتی ہے۔

خطرے کی انتباہ: آپکا سرمایہ خطرے پر ہے۔ ہو سکتا ہے کہ لیورج پروڈکٹ سب کیلیے موزوں نہ ہوں۔ براہ کرم ہمارے مکمل رسک ڈسکلوژر کو پڑھیے۔